Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD

Blood (2018) 132 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2018-99-117333

Published: 2018

Journal Articles

Management of Polycythemia Vera: a Survey of Canadian Physician Practice Plans

Laura Anne Habib, MD, Kevin H.M. Kuo, MD MSc, FRCPC, Tony Panzarella, M.Sc., P.Stat, Vikas Gupta, MD PhD, Martina Trinkaus, MD

Blood (2017) 130 (Supplement 1): 3382.

https://doi.org/10.1182/blood.V130.Suppl_1.3382.3382

Published: 2017

Journal Articles

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Michael D Jain, PhD MD, Lee Mozessohn, MD, Lauren M Gerard, MD, Jackie Ostro, MD, Mansoor Radwi, MD, Bertrand Routy, MD, Bethany Gill, BSc, MMath, Tony Panzarella, M.Sc., P.Stat., Peter Anglin, MD, Matthew C Cheung, Vishal Kukreti, Lisa Hicks, MD MSc

Blood (2014) 124 (21): 2651.

https://doi.org/10.1182/blood.V124.21.2651.2651

Published: 2014

Journal Articles

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Michael Kennah, MD, Nastaran Noroozi, MD FRCPC, Esther Masih-Khan, PhD, Tony Panzarella, M.Sc., P.Stat., Donna E Reece, MD FRCPC, Suzanne Trudel, MD, Vishal Kukreti, MD FRCPC, Rodger Tiedemann, MBChB, PhD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 2019.

https://doi.org/10.1182/blood.V124.21.2019.2019

Published: 2014

Journal Articles

Higher Proportions of IFNg-Producing T Cells, CD56 bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial

Sabine Ivison, PhD, Aminia Kariminia, PhD, Megan Levings, PhD, Raewyn Broady, MBChB, FRACP, Tony Panzarella, M.Sc., P.Stat., Alisha Albert-Green, MSc., Mahmoud Aljurf, M.D., Hind Al Humaidan, MD, FRCPA, Ronan Foley, MD, FRCPC, Gerald Devins, PhD, Holly Margaret Kerr, RN, BSN, Stephanie J Lee, MD, MPH, David Swajcer, MD, MPH, Cynthia L. Toze, MD, FRCP(C), Stephen Couban, M.D., Kirk R. Schultz, MD

Blood (2012) 120 (21): 1944.

https://doi.org/10.1182/blood.V120.21.1944.1944

Published: 2012

NARROW

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Management of Polycythemia Vera: a Survey of Canadian Physician Practice Plans

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Higher Proportions of IFNg-Producing T Cells, CD56 bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Management of Polycythemia Vera: a Survey of Canadian Physician Practice Plans

The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Higher Proportions of IFNg-Producing T Cells, CD56 bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only